Isacco Ferrarini

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.

Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.

Journal: Molecular cancer therapeutics

Published: July 02, 2026

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy.

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy.

Journal: British journal of haematology

Published: May 15, 2026

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Journal: Hematological oncology

Published: February 14, 2026

Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.

Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.

Journal: Leukemia & lymphoma

Published: January 29, 2026

Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series.

Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series.

Journal: Annals of hematology

Published: January 07, 2026

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study.

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study.

Journal: British journal of haematology

Published: November 24, 2025

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease.

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease.

Journal: Hematological oncology

Published: November 18, 2025

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances

Published: October 22, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances

Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances

Published: October 15, 2025

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Journal: Blood advances

Published: June 13, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026